Broad chronic kidney disease labels can mask meaningful biological differences, creating risk for trial design and interpretation. In this sponsored episode of The Top Line, Dr. Ronen Schneider, medical director of renal genetics at Natera, explains how genetic testing and longitudinal clinical data can help development teams define more precise patient populations.
Drawing on FSGS and genetically defined glomerular disease, Schneider examines the implications for natural-history assumptions, endpoint selection, prognostic enrichment and recruitment. He also discusses RenasightIQ, which combines genetic results with clinical histories, longitudinal labs and claims data from more than 300,000 patients.
For translational and clinical development leaders, the takeaway is actionable: evaluate genotype as a trial-design variable. Listen to the podcast to learn how teams can assess hidden heterogeneity in completed studies, ongoing trials and screening populations, then use real-world data to stress-test future development strategies.